Clinical Trial # = NCT01621490
Phase 1 Biomarker study in advanced melanoma
BMS sponsored trial of Nivolumab at 3mg/kg every 2 weeks for 2 years, depending on response, while measuring biomarkers.
Sites actively recruiting include: Los Angeles, Boston, New York, Portland, Nashville, Houston.
Requirements: No brain mets, measurable disease, etc.
Clinical Trial # = NCT01703507
Phase 1 Ipi and Whole brain or SRS in treating melanoma with brain mets
Sites actively recruiting - Thomas Jefferson University, Philadelphia
Will soon be opening at Ohio State University
Clinical Trial # = NCT01672450
Phase 1 with Intratumoral injection of IL2 and ipi in patients with unresectable Stage III or IV
Requires accessible tumors.
Site = Salt Lake City Utah
Clinical Trial # = NCT01497808
Stratified Phase 1/2 - Dose escalation trial of SRS (stereotactic body radiotherapy) followed by ipi in metastatic melanoma.
Sites actively recruiting = Philadelphia
Only 4 of 40 slots filled per site.
Clinical Trial # = NCT01590082
Phase 1/2 - Doxycycline, Temozolomide, and Ipi in Unresectable Stage III/IV melanoma
Site = MD Anderson
Total enrollment to be 58...seems that only 20% have been filled.
(Remember that post about everything killing melanoma??? Well, doxy was on that list!)
Outside the states... Clinical Trial # = NCT01844505
Nivolumab plus ipi OR ipi alone
Sites = US sites appear to be full. Internationally Recruiting= Canada, Italy, Netherlands, Norway, Sweden, Switzerland. Soon to be recruiting = Brazil, Poland, Romania, Russia, South Africa, Turkey
Stage III unresectable or Stage IV, treatment naive, melanoma.
Prior anti-PD1, PDL1 or yervoy = not allowed.
Obviously each trial and site has their own particulars. Check out the link below for more trials and information!!!! Information like this gets outdated quickly! But, the trials I cross referenced with other sites (including NIH) seem to still be enrolling. Please....if you are interested in any of them...CALL the location indicated!
Mdlinx.com for more clinical melanoma trials
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment